(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2015 and the appointment of Gary Littlejohn as Interim Chief Executive Officer as of November 1, 2015. HBP-fiscal-2015-PR-10282015.pdf HBP-fiscal-2015-PR-10282015-1.pdf
Aurora, Ontario – September 30, 2015 – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Mr. Gary Littlejohn has been appointed as a director of Helix, effective as of September 23, 2015. To help facilitate a smooth leadership transition while […]
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Stacy L. Wills has voluntarily resigned from Helix’s board of directors, effective as of September 25, 2015. helix-biopharma-corp-announces-director-resignation-tsx-hbp-2057956.htm helix-biopharma-corp-announces-director-resignation-tsx-hbp-2057956-1.htm
Aurora, Ontario – September 18, 2015 – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Robert Verhagen has resigned as President and Chief Executive Officer (CEO), effective as of November 1, 2015, and as a member of the Board of […]
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, yesterday presented an update of the ongoing clinical study LDOS002 for their drug candidate L‐DOS47 during the 16th World Conference on Lung Cancer held in Denver Colorado. HBP-PR-09-08-15.pdf HBP-PR-09-08-15-1.pdf
L-DOS47 Polish Phase 1 Study Update WCLC2015-L-DOS47-Sept2015.pdf WCLC2015-L-DOS47-Sept2015-1.pdf
Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that an abstract for its lead lung cancer candidate L‐DOS47 has been selected for oral presentation at the 16 World Conference on Lung Cancer (WCLC) held in Denver Colorado, September 6‐9,2015. Aug-24-2015-HBP-Press-Release.pdf
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the thirteenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”). June-22-2015-HBP-Press-Release.pdf
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the third quarter of fiscal 2015, ended April 30, 2015. June-15-2015-HBP-Press-Release.pdf June-15-2015-HBP-Press-Release-1.pdf